15 Apr 2026

NICE Quality Standards on Ovarian Cancer Update

A new statement on CA125 testing and ultrasound has been published today

This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.

The quality standard does not cover risk management and decision-making support for men, trans women and non-binary adults born with male reproductive organs who have, or are at risk of having, a pathogenic variant associated with ovarian cancer.

More details>>